Lynparza shows 'impressive delay' in ovarian cancer disease progression

15 March 2017

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has presented Phase III results showing a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) in the maintenance setting.

Lynparza, AstraZeneca’s oral poly ADP-ribose polymerase (PARP) inhibitor, reduced risk of disease progression by 70% with an investigator-assessed PFS of 19.1 versus 5.5 months with placebo in the SOLO-2 trial, meeting the study’s primary endpoint.

A statistically-significant benefit in time to second progression or death was also seen in patients treated with Lynparza compared with placebo, as well as improvements in other key secondary endpoints.The tablets demonstrated a safety profile generally consistent with previous studies, including a low incidence of hematological toxicity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK